Dr. Mathieu Chellat

Founded in 2005, AGAP2 is a European Operational Engineering consultancy. We operate in the Life-Sciences, Chemistry, Energy, Construction, Transport and IT sectors respectively. AGAP2 currently employs over 3700 qualified scientists and engineers globally that work on projects around the world from our offices in Europe: Switzerland, Germany, Belgium, Spain, France, Netherlands, Portugal, Luxembourg, Sweden and UK.

• Interdisciplinary collaboration project with BioVersys AG, Basel on antibiotic resistance, supported by the Swiss Commission for Technology and Innovation (CTI) • Synthesized over 300 Transcription Repressor Inhibitory Compounds (drug-like small molecules) via multistep chemical synthesis. • Established structure activity relationships for 2 different targets. • Used biological data and modeling studies for the design of new compounds. • Ran PK analytics of in vivo studies on triple-quad UPLC-MS.

• Completed the synthesis of the core of marine macrolide leiodelide A in 17 steps. • Studied the mechanism and improved the yield of the iodooxazole halogen dance reaction from 35% to 81%. • Discovered a one-step procedure for the reduction and deprotection of homoallylic benzyl ethers.

• Synthesis of the core of hepatitis C protease inhibitor boceprevir. • Collaboration with Merck on the synthesis of novel antifungal agents derived from the triterpene glycoside enfumafungin.

Organic Chemistry

Chemistry & Chemical Engineering